This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Acromegaly and pituitary gigantism / GH-secreting adenoma / Somatotroph adenoma말단비대증 및 뇌하수체거인증 (성장호르몬 과잉분비)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E22.0 (acromegaly and pituitary gigantism) | Related: arthropathy associated with acromegaly M14.5* | OMIM: 102200 | Special Copayment Reduction: V112 (rare disease)
B. SynonymsAcromegaly, acromegaly and pituitary gigantism, arthropathy associated with acromegaly (M14.5*), overproduction of growth hormone, pituitary gigantism, pituitary macroadenoma (GH-secreting), growth hormone-secreting pituitary adenoma, Somatotroph adenoma, GH-secreting adenoma, Acromegaly, Pituitary gigantism
C. Adult onsetAdult onset is typical — acromegaly appears when GH/IGF-1 excess develops in adults whose epiphyseal growth plates have closed (soft tissue, bone, and metabolic abnormalities). Pituitary gigantism develops with GH excess in prepubertal children whose growth plates are open. Mean age at diagnosis 40~45 years; characterized by an average diagnostic delay of 7~10 years from symptom onset to diagnosis.
1. History1886 clinical description and naming of acromegaly by Pierre Marie → 1887 association with pituitary tumors established → 1909 introduction of transsphenoidal surgery by Harvey Cushing → 1950s application of radiotherapy → 1970s discovery of somatostatin (Guillemin/Schally, Nobel Prize) → 1980s development of octreotide → 2004 launch of pegvisomant → modern multidisciplinary treatment system.
2. CausesMore than 95% are pituitary GH-secreting adenomas (somatotroph adenomas). GNAS1 mutation (gsp mutation, about 40%) is the most common somatic variant. Rarely, hypothalamic GH-releasing hormone (GHRH)-secreting tumors (carcinoid, pheochromocytoma) or ectopic GH-secreting tumors. Hereditary: MEN1, AIP, X-LAG (XLAG) syndrome.
3. GeneticsSporadic: GNAS1 (Gsα, 20q13.3) gsp mutation about 40%. Hereditary: MEN1 (11q13, MEN1 gene), AIP (11q13.3, aryl hydrocarbon receptor-interacting protein), GPR101 (Xq26.3, X-LAG), PRKAR1A (Carney complex). AIP variants: onset in young adulthood, macroadenoma, resistance to somatostatin analogs. Hereditary cases account for about 5% of the total.
4. General epidemiologyPrevalence about 40~70 per million, incidence 3~4 per million per year. Equal by sex, but reports of longer diagnostic delay in women. Mean age at diagnosis 40~45 years. Average diagnostic delay 7~10 years. In Korean health insurance data, incidence and prevalence are similar to or slightly lower than in the West. Pituitary gigantism is rarer (about 10% or less of acromegaly).
5. PathophysiologySomatotroph adenoma → persistent GH oversecretion → overproduction of IGF-1 (insulin-like growth factor-1) in the liver → stimulation of systemic tissue growth. Direct GH effects (soft tissue hypertrophy, insulin resistance) + IGF-1-mediated effects (enlargement of bone, cartilage, and viscera). GNAS1 gsp mutation: Gsα activation → persistent cAMP increase → GH oversecretion + adenoma cell proliferation.
6. SymptomsChanges in facial appearance (enlarged nose and lips, mandibular protrusion, frontal prominence), increased size of hands and feet (increased ring and shoe sizes), headache, visual disturbances (tunnel vision, visual field defects), snoring and sleep apnea, joint pain, increased sweating, hoarse voice, fatigue, decreased libido and menstrual irregularities. Metabolic and cardiovascular complications such as diabetes, hypertension, and heart failure.
7. SignsCoarsened facial features, enlarged hands and feet with thick, broad fingertips, prognathism, increased interdental spacing, goiter, visceromegaly (heart, liver, spleen), skin thickening and increased sebum secretion, carpal tunnel syndrome, elevated serum IGF-1, failure of GH suppression (GH ≥ 1 μg/L after glucose load).
8. ScreeningWhen clinically suspected, measurement of serum IGF-1 (age- and sex-adjusted normal reference range) is the first-line screen. If IGF-1 is elevated, failure of GH suppression on the oral glucose tolerance test (OGTT) is confirmed (nadir GH ≥ 1 μg/L at 60~120 minutes after 75 g glucose). Random serum GH fluctuates greatly and is unsuitable for screening. If a hereditary form is suspected, family history + AIP/MEN1 gene testing.
9. DiagnosisElevated IGF-1 + failure of GH suppression on OGTT → biochemical diagnosis. Pituitary MRI (gadolinium contrast, dynamic MRI) to evaluate adenoma location, size, and cavernous sinus invasion. Visual field testing (Goldman or Humphrey perimetry). Echocardiography (myocardial hypertrophy, valve abnormalities). Polysomnography (sleep apnea). Colonoscopy (polyp risk). Evaluation of associated arthropathy (X-ray, MRI).
10. TreatmentFirst-line: transsphenoidal surgery (TSS) is the standard treatment for microadenomas and accessible macroadenomas. Medications: somatostatin analogs (octreotide LAR, lanreotide), dopamine agonists (cabergoline), pegvisomant (GH receptor antagonist). Radiotherapy: inoperable or residual tumor. Treatment goals: normalization of IGF-1, GH < 1 μg/L (glucose suppression), tumor removal/reduction.
11. PrognosisWithout treatment, life expectancy is shortened by 10 years. With biochemical remission, mortality is similar to that of the general population. Main causes of death: cardiovascular disease, respiratory disease, malignancy. With diagnostic delay and inadequate treatment, the risks of diabetes, cardiomyopathy, osteoarthritis, and colorectal cancer continue to increase. Early diagnosis and treatment are decisive for prognosis.
12. PreventionPrimary prevention not possible (no established method to prevent tumor development). Secondary prevention: early diagnosis (improved recognition of facial changes and increasing shoe size), achievement of biochemical remission. Tertiary prevention: ongoing management of cardiovascular and metabolic complications, colorectal cancer screening (colonoscopy every 5 years), rehabilitation for arthropathy, hormone replacement therapy for hypopituitarism.
13. ReferencesMelmed S et al. Acromegaly (Endocrine Society Clinical Practice Guideline, 2018) and 9 other key papers

1. History

The history of acromegaly began in the golden age of French neurology in the late 19th century. In 1886, the French neurologist Pierre Marie systematically described, under the new name "acromegaly (acromégalie)," the characteristic physical changes observed in two patients—namely, the gradual enlargement of the hands, feet, face, and skull, especially overgrowth of the extremities (acra: Greek for extremities) and facial bones—and reported them in Revue de Médecine. Marie proposed the hypothesis that this disease was related to the pituitary gland, but the exact cause was not elucidated at the time. In 1887, pituitary tumors (adenomas) were consistently found in patients with acromegaly at postmortem autopsies by pathologists, establishing the causal relationship with the pituitary gland.

In the early 20th century, the American neurosurgeon Harvey Cushing, a pioneer of pituitary surgery, developed pituitary tumor surgery via the transsphenoidal approach in 1909. Cushing described the clinical stages of acromegaly in detail and proposed that hyperplasia of the acidophilic cells of the anterior pituitary (acidophilic cells, now somatotrophs) was the cause of GH excess. This transsphenoidal surgery subsequently became the standard surgical approach for acromegaly for almost a century and is still used as first-line treatment today.

In the mid-20th century, the biochemical properties of growth hormone (GH) itself began to be elucidated. In the 1960s, the development of radioimmunoassay (RIA) made it possible to measure serum GH directly, and in the 1970s, failure of GH suppression after a glucose load was established as a diagnostic criterion for acromegaly. In 1970~73, Roger Guillemin and Andrew Schally isolated and identified somatostatin (growth hormone-inhibiting hormone, GHIH) from the hypothalamus, and for this achievement the two researchers received the 1977 Nobel Prize in Physiology or Medicine. The discovery of somatostatin later became the foundation for the development of somatostatin analog drugs (octreotide, lanreotide).

In the 1980s, the somatostatin analog octreotide was synthesized, developed, and introduced into clinical practice (FDA approval 1988). This became a revolutionary turning point in drug therapy for acromegaly, and its effect in suppressing pituitary GH secretion and normalizing GH and IGF-1 levels was demonstrated. In the 1990s, long-acting octreotide (Sandostatin LAR, intramuscular injection once a month) and lanreotide (Somatuline Autogel, subcutaneous injection every 4 weeks) were developed, enabling more convenient long-term treatment.

In 2004, the GH receptor antagonist pegvisomant received FDA approval and became established as the third pharmacological pillar of acromegaly treatment. Pegvisomant has a unique mechanism: rather than suppressing GH secretion itself, it blocks the action of GH at the GH receptor level to suppress IGF-1 production, and it shows a very high (95% or more) IGF-1 normalization rate in patients resistant to somatostatin analogs.

In the 21st century, advances in endoscopic endonasal transsphenoidal surgery (EETS) greatly improved the surgical field of view and precision, and Gamma Knife (stereotactic radiosurgery) radiosurgery was established as an effective treatment option for inoperable residual tumors. In 2018, the Endocrine Society published the latest clinical practice guideline for acromegaly, which is currently used as the reference guideline for acromegaly management worldwide.


2. Causes

More than 95% of acromegaly is caused by a pituitary adenoma arising from somatotroph cells of the anterior pituitary. By size, adenomas are classified as microadenomas (less than 1 cm in diameter) and macroadenomas (1 cm or more), and in patients with acromegaly, most (about 75%) are characteristically macroadenomas at the time of diagnosis. This reflects the fact that symptoms of acromegaly progress slowly over years, delaying diagnosis.

Somatic mutations in somatotroph adenomas

The most common somatic mutation found in somatotroph adenomas is an activating mutation ("gsp mutation") of the GNAS1 (guanine nucleotide-binding protein alpha-stimulating subunit, Gsα) gene. GNAS1 mutations are found in about 30~40% of all sporadic somatotroph adenomas. Normally, Gsα is transiently activated by GH-releasing hormone (GHRH) receptor signaling and then inactivated by its intrinsic GTPase activity. The gsp mutations of GNAS1 (mainly Arg201His, Arg201Cys, Gln227Arg, Gln227Lys) abolish the GTPase activity of Gsα, so that Gsα remains persistently activated. As a result, cAMP (cyclic adenosine monophosphate) increases persistently, promoting GH oversecretion and cell proliferation in somatotroph cells. Adenomas with gsp mutations tend to be smaller and to respond better to somatostatin analogs than gsp-negative adenomas.

Causes of hypothalamic origin

Rarely (1~2% of all acromegaly), tumors that oversecrete GHRH from the hypothalamus can cause acromegaly. Ectopic GHRH-secreting tumors include bronchial carcinoid, pancreatic neuroendocrine tumors, and pheochromocytoma; in these cases, the pituitary shows diffuse somatotroph hyperplasia under GHRH stimulation and oversecretes GH. Acromegaly due to ectopic GH-secreting tumors (e.g., pancreatic cancer, lymphoma) is extremely rare. GHRH-induced causes are differentiated by measurement of serum GHRH and a search for chest and abdominal tumors by CT/MRI.

Hereditary causes

A genetic cause is identified in about 5% of all acromegaly, and it should be suspected especially with onset at a young age or a family history. The main hereditary syndromes are: MEN1 (multiple endocrine neoplasia type 1): MEN1 gene (11q13) variants causing the triad of parathyroid, pituitary, and pancreatic tumors, with about 10~15% of pituitary adenomas being GH-secreting; AIP gene (aryl hydrocarbon receptor-interacting protein) variants: a cause of sporadic or familial pituitary adenoma (FIPA, familial isolated pituitary adenoma), characterized by onset in young adulthood (20s~30s) or childhood, large GH-secreting adenomas, and resistance to somatostatin analogs; X-LAG syndrome (X-linked acrogigantism): caused by duplication of the GPR101 gene (Xq26.3), with gigantism appearing from early infancy and the most severe GH excess in children; Carney complex: PRKAR1A gene variants, with a combination of cutaneous myxomas, pigmentation, cardiac myxomas, and endocrine tumors.


3. Genetics

The genetics of acromegaly should be understood by dividing it into somatic molecular changes of sporadic tumors and germline mutations of hereditary syndromes.

Molecular genetics of sporadic somatotroph adenomas

Besides the GNAS1 gsp mutation described above, molecular changes found in somatotroph adenomas include CDKN1B (p27Kip1) mutations (MEN4 syndrome), SDH (succinate dehydrogenase) subunit mutations, and variants of CABLES1, MEN1, RB1, PTTG1, and others. Studies using whole exome sequencing (WES) have shown that, unlike other malignant tumors, somatotroph adenomas have a low mutation burden and a relatively simple clonal structure. This is consistent with the biological characteristic that most somatotroph adenomas behave benignly.

The AIP gene and familial isolated pituitary adenoma (FIPA)

The AIP (aryl hydrocarbon receptor-interacting protein) gene is located on the long arm of chromosome 11 (11q13.3) and functions as a tumor suppressor gene. AIP interacts with the aryl hydrocarbon receptor (AHR), phosphodiesterases, and others and is involved in inhibiting cell proliferation. When there are AIP loss-of-function variants (more than 60 pathogenic variants reported, including missense, nonsense, splice-site, and deletion variants), cAMP degradation is impaired, promoting GH oversecretion and somatotroph cell proliferation. The features of AIP variant-positive acromegaly are ① onset at a young age (average 20s~30s, including children), ② a high proportion of macroadenomas, ③ poor response to somatostatin analog treatment (associated with reduced SSTR2 expression), and ④ increased tumor invasiveness. These features suggest that pegvisomant or combination therapy is often needed for AIP variant adenomas.

GPR101 and X-LAG syndrome

X-linked acrogigantism (X-LAG) is caused by a copy number variant (microduplication) of the GPR101 gene located on the long arm of the X chromosome (Xq26.3). GPR101 is a G protein-coupled receptor (orphan GPCR) that constitutively activates the cAMP pathway in pituitary somatotrophs. Rapid growth acceleration and GH/PRL excess appear in early life (a few months to 3 years after birth), and pituitary somatotroph adenomas or mixed adenomas (GH+PRL-secreting) are characteristic. It occurs in both boys and girls, but there are also many sporadic cases with the X-linked transmission pattern.


4. General epidemiology

Acromegaly is a rare endocrine disease but causes serious systemic complications. Epidemiological knowledge is important for decisions on active testing in suspected patients and for public health policy making.

Worldwide prevalence and incidence

Worldwide, the prevalence of acromegaly is estimated at about 40~70 per million population. Recent systematic literature reviews and large epidemiological studies report a higher prevalence than previous estimates (up to 130 per million), reflecting improved diagnostic technology and increased awareness. The annual incidence is estimated at 3~4 per million population. European data (Spain, Germany, the UK, the Czech Republic, etc.) report prevalence at the level of 60~100 per million, and data from Asia and other regions are limited.

Epidemiology in Korea

In Korea, the incidence and prevalence of acromegaly are being determined through studies using health insurance claims data. The domestic prevalence is reported at about 30~50 per million population, similar to or slightly lower than in the West. In Korea as well, the diagnosis rate is improving with recent advances in MRI technology, an increase in endocrine centers specializing in pituitary disease, and improved awareness of acromegaly among medical staff. Construction of pituitary tumor registries centered on university hospitals and endocrine specialty centers nationwide is underway, and domestic epidemiological data are gradually accumulating.

Diagnostic delay

A characteristic epidemiological problem of acromegaly is long diagnostic delay. The period from symptom onset to final diagnosis is reported to average 7~10 years. This is because facial and bodily changes occur very gradually and the patients themselves often do not notice them. It is common for relatives or physicians to notice changes in appearance by comparison with old photos, or for the diagnosis to be made when the patient visits other departments for complications such as sleep apnea, diabetes, hypertension, or joint pain. Primary care education and public awareness campaigns to shorten diagnostic delay are important.

Sex and age distribution

Acromegaly occurs almost equally in men and women, but some studies report longer diagnostic delays in women. This suggests that in women, the typical symptoms of acromegaly (facial changes, voice changes) may be overlooked as cosmetic or vocal changes. Age of onset is usually in the 30s~50s, and the mean age at diagnosis is 40~45 years. Onset in childhood and adolescence (gigantism) is rare but relatively more common with AIP variants and X-LAG syndrome.


5. Pathophysiology

The core pathophysiology of acromegaly is oversecretion of growth hormone (GH) by a somatotroph adenoma, the resulting overproduction of insulin-like growth factor-1 (IGF-1), and excessive growth stimulation of systemic tissues.

Normal mechanism of GH regulation

Normally, when GH-releasing hormone (GHRH) is secreted from the hypothalamus, GH secretion from pituitary somatotrophs is stimulated, and somatostatin (SRIH/somatostatin) inhibits GH secretion. Secreted GH stimulates IGF-1 production in the liver, and when IGF-1 increases, it sends negative feedback to the hypothalamic-pituitary axis to suppress GH secretion. In addition, a rise in glucose (after meals) stimulates hypothalamic somatostatin secretion and suppresses GH secretion; the oral glucose tolerance test (OGTT) makes use of this mechanism.

Mechanism of GH excess in somatotroph adenomas

Somatotroph adenoma cells escape the negative feedback regulation of normal somatotrophs and continuously secrete GH autonomously. In adenomas with the GNAS1 gsp mutation, Gsα cannot be inactivated and remains persistently active, so cAMP levels remain persistently high. High cAMP persistently activates protein kinase A (PKA), and PKA phosphorylates the transcription factor CREB (cAMP response element-binding protein), promoting GH gene transcription and GH secretion. Even in adenomas without gsp variants, abnormal activation of other intracellular signaling pathways (MAPK, PI3K/Akt, etc.) maintains autonomous GH secretion.

Direct GH effects and IGF-1-mediated effects

Oversecreted GH acts on tissues through two pathways. First, direct GH effects: stimulation of lipolysis (mobilization of free fatty acids), anti-insulin action (inducing insulin resistance, increasing hepatic glucose production), and stimulation of renal sodium and water reabsorption (causing edema). Second, IGF-1-mediated effects: when GH binds to hepatic GH receptors, hepatic IGF-1 synthesis and secretion increase greatly. IGF-1 induces cell proliferation and growth stimulation in systemic tissues via the IGF-1 receptor. Specifically, cartilage and bone growth (bone enlargement, joint overgrowth), soft tissue hypertrophy (soft tissues of the hands and feet; enlargement of the nose, lips, tongue, and vocal cords), visceromegaly (enlargement of the heart, liver, spleen, kidneys, and thyroid), skin thickening, and sebaceous gland hyperactivity occur.

Mechanism of metabolic complications

GH directly increases insulin secretion from pancreatic β cells while impairing post-insulin-receptor signaling in peripheral tissues (muscle, fat), causing insulin resistance. As a result, diabetes or impaired glucose tolerance develops in 25~40% of acromegaly patients. In the heart, GH and IGF-1 cause cardiomyocyte hypertrophy, interstitial fibrosis, and cardiac autonomic dysfunction, leading to acromegalic cardiomyopathy. Hypertension occurs in about 40%, and sleep apnea is due to hypertrophy of upper airway soft tissues.

Mechanism of arthropathy (M14.5*)

IGF-1 excess promotes the growth and division of articular chondrocytes, initially causing cartilage thickening. However, persistent GH/IGF-1 excess and increased joint loading promote cartilage degradation, leading to synovial hypertrophy, joint space widening followed by narrowing, and joint hyperplasia and deformity. Unlike this arthropathy associated with sarcoidosis, acromegalic arthropathy is characterized by joint deformity due to bone overgrowth, with severe degenerative joint changes in the knee, hip, shoulder, and spinal joints.


6. Symptoms

The symptoms of acromegaly reflect the systemic effects of GH/IGF-1 excess and can be broadly divided into changes in facial and limb appearance, intracranial tumor effects, and metabolic, cardiovascular, and musculoskeletal complications.

Changes in appearance (face, hands and feet, skeleton)

The most characteristic symptom of acromegaly is slowly progressive change in appearance. In the face, changes appear in the nose (enlarged nostrils and widening of the nose), lips (thickening), ears, brow (frontal bossing, forehead protrusion), and protrusion of the cheekbones. In particular, prognathism, in which the mandible protrudes forward, and diastema, in which gaps form between the teeth, are characteristic. In the hands and feet, soft tissue hypertrophy thickens the fingers and broadens the hands overall, and patients themselves commonly notice that their shoe size has become larger than decades ago. Difficulty putting on rings, or existing rings no longer fitting, is also a characteristic symptom. These changes in appearance progress slowly over years to decades, and often neither the patient nor close family members notice them.

Symptoms due to the pituitary tumor

Headache due to pituitary macroadenoma is very common (50~75%) and occurs when the tumor stretches the pituitary capsule or compresses structures around the sella turcica. Visual field abnormalities occur when a macroadenoma compresses the optic chiasm, typically producing bitemporal hemianopsia. If visual decline progresses, permanent visual impairment can remain, so early detection is important. Hypopituitarism: when a macroadenoma compresses the normal pituitary, deficiencies of gonadotropins, thyroid-stimulating hormone, and adrenocorticotropic hormone develop, causing decreased libido, infertility, fatigue, and cold intolerance. Hyperprolactinemia: about 30~40% of GH-secreting adenomas cosecrete PRL, or compression of the pituitary stalk impairs delivery of prolactin-inhibiting hormone (dopamine), causing menstrual irregularity, amenorrhea, and galactorrhea in women and decreased libido and erectile dysfunction in men.

Metabolic symptoms

Increased sweating (hyperhidrosis) and increased sebum secretion are among the most common (about 60~70%) symptoms of acromegaly and are also useful indicators for evaluating treatment response. Sleep apnea occurs in 50~80%, most commonly obstructive sleep apnea due to hypertrophy of upper airway soft tissues (enlargement of the tongue, tonsils, and uvula). Sleep apnea is an important contributor to cardiovascular complications (hypertension, arrhythmia). Diabetes or impaired glucose tolerance (25~40%), hypertension (40%), and hyperlipidemia are also common metabolic abnormalities.

Musculoskeletal symptoms

Joint pain and arthropathy (M14.5*) are among the most common complications of acromegaly (40~70%), with pain, stiffness, and limited range of motion in the knees, hips, shoulders, finger joints, and elsewhere. This results from overgrowth followed by degeneration of articular cartilage, bone overgrowth, and synovial hypertrophy, and often remains as an irreversible change with limited recovery even after treatment. Carpal tunnel syndrome appears in 30~60% of acromegaly patients and is characterized by hand numbness, nocturnal pain, and weakness of the proximal thumb due to median nerve compression from hypertrophy of the wrist ligaments and soft tissues.


7. Signs

On physical examination, characteristic changes in appearance and complication-related findings of acromegaly are observed.

Appearance and physical findings

Coarsened facial features: enlargement of the nose, lips, and brow, skin thickening (thick, oily skin), prognathism, increased interdental spacing. Acral enlargement: large, broad hands and feet, thick fingers with broad, rim-like tips (spade-like hands), spatula-shaped feet. Gigantism: with onset before the growth plates close, pituitary gigantism with very tall stature appears (accompanied by tall stature and enlarged facial features). Visceromegaly: thyroid enlargement (may be accompanied by thyroid nodules), cardiac enlargement (increased heart sounds and murmurs on auscultation), hepatosplenomegaly (palpable). Skin findings: excessive sebum secretion, skin tags (a characteristic cutaneous manifestation of acromegaly, associated with colon polyps and malignant tumors), hyperhidrosis.

Test findings

Elevated serum IGF-1 is the most important biochemical indicator of acromegaly. Serum IGF-1 must be interpreted using an age- and sex-adjusted normal reference range, and when elevated, failure of GH suppression is confirmed by OGTT. Failure of GH suppression after OGTT: GH is measured at 0, 30, 60, 90, and 120 minutes after oral administration of 75 g glucose, and failure of suppression is defined as nadir GH remaining at or above 1 μg/L (0.4 μg/L with ultrasensitive assays). Pituitary MRI evaluates the size and location of the adenoma, cavernous sinus invasion, and distance from the optic chiasm. Visual field testing reveals bitemporal hemianopsia or eccentric visual field defects.

Findings of related complications

Echocardiography: left ventricular hypertrophy (LVH), myocardial thickening, diastolic dysfunction, valvular regurgitation. Holter ECG: arrhythmias (ventricular ectopy, atrial fibrillation). Polysomnography: elevated obstructive sleep apnea index (AHI). Nerve conduction study: delayed median nerve conduction in carpal tunnel syndrome. Joint X-ray: enlargement of the terminal phalanges (terminal tuft), changes in joint space, spinal kyphoscoliosis, osteophyte formation. Colonoscopy: colon polyps (1.5~3 times more frequent than in the general population).


8. Screening

The key to screening for acromegaly is clinical suspicion. Because symptoms progress slowly and diagnosis is easily delayed, screening tests are performed when the following clinical clues are present.

Clinical screening situations

① Changes in facial appearance (enlargement of the nose, forehead, mandible) with gradual increases in shoe, glove, and ring sizes; ② unexplained headache + visual field abnormalities; ③ early-onset diabetes (especially with an appearance suggestive of acromegaly); ④ unexplained hypertension + sleep apnea + hyperhidrosis; ⑤ bilateral carpal tunnel syndrome; ⑥ early-onset, rapidly progressive arthropathy; ⑦ multinodular goiter (consider hereditary syndromes such as MEN1); ⑧ family history of acromegaly or MEN1/AIP/X-LAG; ⑨ unexplained colon polyps or a family history of colorectal cancer (when accompanied by skin tags).

First-line screening tests

Serum IGF-1 measurement: An age- and sex-adjusted normal reference range (IGF-SDS or age-specific normal range) is used. IGF-1 shows little diurnal variation, so blood can be drawn at a random time; its sensitivity for acromegaly is over 90% and its specificity over 97%. However, situations in which IGF-1 may be low (malnutrition, liver failure, hypothyroidism, diabetes, etc.) must be considered. If IGF-1 is elevated, a confirmatory test (OGTT) is performed.

Confirmatory tests

Oral glucose tolerance test (OGTT): serum GH measured at 0, 30, 60, 90, and 120 minutes after oral administration of 75 g glucose. If nadir GH is ≥ 1 μg/L (or ≥ 0.4 μg/L with high-sensitivity assays), suppression has failed and acromegaly is diagnosed. Typically, both criteria—elevated IGF-1 + failure of suppression on OGTT—are met. When the two tests are discordant, clinical judgment and MRI findings are integrated.

Imaging and functional tests

Pituitary MRI (gadolinium contrast, including a dynamic protocol): must be performed after the primary biochemical diagnosis is established. Distance from the optic chiasm, cavernous sinus invasion (Knosp classification), and adenoma size are evaluated to determine surgical suitability and approach. Even if pituitary MRI is negative, when the biochemical diagnosis has been established, ectopic GHRH-secreting tumors are evaluated (chest and abdominal CT/MRI).


9. Diagnosis

Diagnosis of acromegaly consists of three steps: ① biochemical confirmation, ② imaging confirmation of the tumor, and ③ evaluation of accompanying complications.

Biochemical diagnosis

According to the 2018 Endocrine Society guideline, the biochemical diagnosis of acromegaly is defined as follows: ① serum IGF-1 above the age- and sex-adjusted upper limit of normal, AND ② nadir GH ≥ 1 μg/L after OGTT (75 g) (or ≥ 0.4 μg/L with ultrasensitive assays). Random serum GH is not used as a diagnostic criterion because secretion is pulsatile. However, when serum GH is below 0.4 μg/L, acromegaly is almost excluded.

Pituitary MRI evaluation

Gadolinium-enhanced pituitary MRI evaluates the location of the somatotroph adenoma, its size (microadenoma < 1 cm, macroadenoma ≥ 1 cm), whether there is cavernous sinus invasion (Knosp grade 0~4), and whether there is optic chiasm compression. Cavernous sinus invasion is a major obstacle to complete resection and is therefore essential information for preoperative planning. Some adenomas may not be visible on MRI (microadenoma < 3 mm); in such cases, evaluation for ectopic causes together with interpretation by an experienced neuroradiologist is important.

Evaluation of complications

After the diagnosis is established, the following complications are systematically evaluated: ① visual field testing (with suprasellar tumor extension), ② echocardiography (myocardial hypertrophy, diastolic function, valves), ③ polysomnography (sleep apnea), ④ blood glucose and HbA1c (diabetes evaluation), ⑤ blood pressure (hypertension), ⑥ joint X-ray and MRI (arthropathy), ⑦ colonoscopy (polyps, malignancy), ⑧ overall evaluation of pituitary function (function of hormone axes other than GH), ⑨ osteoporosis evaluation (DEXA, when accompanied by GH deficiency or hypogonadism). When a hereditary syndrome is suspected (family history, onset before age 25, multiple tumors), AIP and MEN1 gene testing and evaluation of parathyroid and pancreatic function.

Biochemical remission criteria after treatment

The biochemical criteria for treatment success (remission) are ① serum IGF-1 within the age- and sex-adjusted normal range, and ② nadir GH < 1 μg/L after OGTT (< 0.4 μg/L with ultrasensitive assays). When both criteria are met, biochemical remission is determined.


10. Treatment

The treatment goals of acromegaly are ① normalization of GH/IGF-1, ② removal or reduction of the pituitary tumor, ③ preservation of normal pituitary function, and ④ control of related complications (cardiovascular, metabolic, musculoskeletal). Treatment rests on three pillars—surgery, medication, and radiotherapy—and a combined treatment strategy is established according to each patient's situation.

Surgery (transsphenoidal surgery, TSS)

Transsphenoidal surgery (TSS) is the first-line treatment for acromegaly. Currently, endoscopic endonasal transsphenoidal surgery (EETS) is the standard. The surgical goal is gross total resection of the adenoma. The surgical remission rate for microadenomas is about 75~90%, falling to the level of 40~60% for macroadenomas (especially with cavernous sinus invasion). Surgical complications include transient or permanent diabetes insipidus, cerebrospinal fluid leak, hypopituitarism, optic nerve injury, and meningitis, but their incidence at specialized pituitary surgery centers is low. At 3 months after surgery, IGF-1 and OGTT-GH are measured to determine remission.

Somatostatin analogs (SSA)

Octreotide LAR (10~40 mg/4 weeks intramuscularly) and Lanreotide Autogel (60~120 mg/4 weeks subcutaneously) are the main SSAs. SSAs bind to somatostatin receptors (mainly SSTR2, SSTR5), suppressing GH secretion and inhibiting tumor growth. Indications are ① first-line medical therapy when surgery is not possible or the patient refuses surgery, ② residual or recurrent tumor after surgery, and ③ bridging therapy while awaiting radiotherapy. In randomized studies, the IGF-1 normalization rate is about 40~55%. The main side effects are gallstones (about 20~30% with long-term use), gastrointestinal symptoms (nausea, diarrhea, abdominal discomfort), and fluctuations in glycemic control (improved insulin sensitivity due to GH suppression, but direct suppression of insulin secretion). Pasireotide (0.3~0.9 mg/day subcutaneously or 40~60 mg/4 weeks LAR intramuscularly) is a second-generation SSA that, unlike first-generation SSAs, binds SSTR1, 2, 3, and 5 all with high affinity; it is used when the response to first-generation SSAs is insufficient, but hyperglycemic side effects are more frequent.

Pegvisomant (GH receptor antagonist)

Pegvisomant (10~30 mg/day subcutaneously) competitively blocks the GH-binding site of the GH receptor (GHR), suppressing IGF-1 production in the liver. It is used alone or in combination with an SSA when the response to SSAs is insufficient, and its IGF-1 normalization rate is very high, over 90%. Important cautions are ① because pegvisomant does not suppress GH secretion itself, serum GH may actually increase; ② because it does not directly suppress tumor size, MRI follow-up monitoring is needed (increase in tumor size reported in about 3%); and ③ elevated liver enzymes (2~5%) may occur, so regular LFT monitoring is needed. It has the additional benefit of improving insulin sensitivity in acromegaly with diabetes.

Dopamine agonists

Cabergoline (0.5~3.5 mg/week orally) suppresses GH secretion via pituitary dopamine D2 receptors. When used alone, the IGF-1 normalization rate is about 35% or less, lower than SSAs, but when combined with an SSA it has an additional GH/IGF-1-lowering effect and the advantage of convenient oral administration. It is particularly effective in adenomas that cosecrete GH and PRL.

Radiation therapy

Gamma Knife stereotactic radiosurgery (GKRS) is the most commonly used pituitary radiotherapy. It is performed for residual tumor after surgery, inoperable cases, and medication-refractory cases. Biochemical remission (IGF-1 normalization) is achieved gradually over an average of 5~10 years after treatment (about 30~60%), and medical therapy must be continued during the radiotherapy period. The main side effects are hypothalamic-pituitary dysfunction (long-term incidence about 30~50%), rarely radiation-induced optic neuropathy, and secondary brain tumors (extremely rare).

Complication-specific treatment

Complications are treated concurrently with treatment of acromegaly itself. Diabetes: glycemic control (improvement in insulin resistance is expected with GH/IGF-1 normalization, but medication continues in advanced diabetes). Hypertension: standard antihypertensive treatment. Sleep apnea: CPAP treatment (sleep apnea may improve in about 40% after GH/IGF-1 normalization). Arthropathy (M14.5*): nonsteroidal anti-inflammatory drugs, physical therapy, and joint replacement in severe cases. Carpal tunnel syndrome: splints, steroid injection, surgical release. Hypopituitarism: replacement of each deficient hormone (thyroid hormone, cortisol, sex hormones, growth hormone).


11. Prognosis

Acromegaly is a serious systemic disease that, if untreated, shortens life expectancy by about 10 years. However, when biochemical remission is achieved, mortality can normalize to a level similar to that of the general population.

Mortality and biochemical remission

The standardized mortality ratio (SMR) of patients with acromegaly before treatment is 1.5~3.0, higher than that of the general population. However, in patients who achieve biochemical remission (IGF-1 normalization + GH suppression), the SMR approaches 1.0 and normal mortality is restored. In contrast, mortality remains high in patients whose IGF-1 remains elevated even after treatment. Therefore, achieving strict biochemical remission, the goal of treatment, is decisive for prognosis.

Main causes of death

Among the main causes of death in acromegaly, cardiovascular disease (about 60%) is the most important, resulting from acromegalic cardiomyopathy, hypertension, atrial fibrillation, heart failure, and others. Respiratory disease (including sleep apnea-associated cardiovascular complications, about 25%) and malignancy (increased risk of colorectal and thyroid cancer, about 15%) follow. These causes of death can be prevented by early diagnosis and achievement of biochemical remission.

Reversibility and irreversibility of complications

After biochemical remission is achieved, reversible complications include hyperhidrosis (mostly improves), sleep apnea (improves in about 40%), diabetes and impaired glucose tolerance (improved insulin resistance), hypertension (partial improvement), carpal tunnel syndrome (improves in about half), and headache (mostly improves). In contrast, irreversible or partially reversible complications include arthropathy (cartilage and bone damage that has already occurred), changes in facial and skeletal appearance (mostly irrecoverable), visceromegaly (partial recovery), and myocardial hypertrophy (partial recovery). This emphasizes that early diagnosis and early treatment are decisive in preventing irreversible complications.

Tumor recurrence

Even in patients who achieve biochemical remission after surgery, tumor recurrence is reported in 5~15%. It is more common especially with macroadenomas. On recurrence, additional treatment such as reoperation, somatostatin analog therapy, or radiotherapy is needed. Therefore, regular follow-up of IGF-1, GH, and pituitary MRI is essential even after surgery.


12. Prevention

Because acromegaly is caused by sporadic pituitary adenomas, primary prevention is difficult. However, secondary and tertiary prevention strategies to prevent complications and improve quality of life are very important.

Primary prevention: family screening for hereditary syndromes

No method of primary prevention for sporadic acromegaly is currently known. However, in families in which a hereditary syndrome (MEN1, AIP variant FIPA, X-LAG, Carney complex) has been identified, screening of family members for mutation carriers is performed, and early detection is possible in identified carriers through regular pituitary MRI and IGF-1 follow-up. For AIP variant carriers in particular, it is recommended that regular testing begin from adolescence.

Secondary prevention: early diagnosis and achievement of biochemical remission

The most important secondary prevention strategy for improving the prognosis of acromegaly is shortening diagnostic delay. Through education of general practitioners and specialists, awareness is raised so that acromegaly is included in the differential diagnosis for changes in facial appearance, acral enlargement, hyperhidrosis, sleep apnea, and the combination of hypertension and diabetes. Achieving biochemical remission through prompt surgery and medical therapy after early diagnosis is key to preventing cardiovascular and metabolic complications.

Tertiary prevention: management of long-term complications

Cardiovascular complications: optimization of hypertension and diabetes treatment, lipid management, regular echocardiography, polysomnography follow-up. Colorectal cancer prevention: because the risk of colon polyps and colorectal cancer in patients with acromegaly is higher than in the general population, colonoscopy is performed at diagnosis and then every 5 years (more frequently if skin tags are present or colon polyps have been found). Osteoporosis prevention: DEXA testing and hormone replacement therapy when hypopituitarism accompanies. Arthropathy rehabilitation: physical and exercise therapy for irreversible joint changes, and joint replacement if needed. Hypopituitarism: regular evaluation and hormone replacement therapy (thyroid hormone, cortisol, sex hormones, etc.) for hypopituitarism occurring after surgery or radiotherapy. Regular follow-up: IGF-1 and GH (at least every 6 months~1 year), pituitary MRI (3 months after surgery, then every 1~2 years), and follow-up of complication indicators.


13. References

  1. Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–561. DOI: 10.1038/s41574-018-0058-5. PMID: 30050156.

  2. Katznelson L, Laws ER Jr, Melmed S, et al.; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951. DOI: 10.1210/jc.2014-2700. PMID: 25356808.

  3. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189–3202. DOI: 10.1172/JCI39375. PMID: 19884662.

  4. Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20. DOI: 10.1038/s41572-019-0071-6. PMID: 30899019.

  5. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41(1):95–102. DOI: 10.1111/j.1365-2265.1994.tb03789.x. PMID: 8050126.

  6. Giustina A, Chanson P, Bronstein MD, et al.; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141–3148. DOI: 10.1210/jc.2009-2670. PMID: 20410227.

  7. Espinosa-de-los-Monteros AL, González B, Vargas G, Sosa E, Mercado M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary. 2011;14(3):231–235. DOI: 10.1007/s11102-010-0278-y. PMID: 21136179.

  8. Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab. 2000;85(1):168–174. DOI: 10.1210/jcem.85.1.6309. PMID: 10634385.

  9. Rostomyan L, Daly AF, Petrossians P, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015;22(5):745–757. DOI: 10.1530/ERC-15-0320. PMID: 26187128.

  10. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87(1):99–104. DOI: 10.1210/jcem.87.1.8153. PMID: 11788633.